Clinical Trial Update: A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome [Phase 1, Phase 2]

View source ↗

Summary

Ultragenyx reports the completed Phase 1/2 study evaluating the safety and tolerability of GTX-102 in children with Angelman syndrome. The trial was sponsored b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angelman Syndrome

Drugs mentioned

• GTX-102

Snippet

Sponsor: Ultragenyx Pharmaceutical Inc | Conditions: Angelman Syndrome | Phase 1, Phase 2 | Status: COMPLETED